Table 2.
Characteristics of PLCRC participants at diagnosis (2013-Aug’19), compared with the general Dutch CRC population (2013–’17), and stratified by time-period (2013–’16, and 2017–Aug’19).
| Baseline characteristics | Dutch population with CRC between 2013- ‘17 (n = 72,685) | All PLCRC participants 2013-Aug’19 (n = 4759) | Standardized difference (d)a | PLCRC’s initial phase 2013-’16 (n = 1088) | Standardized difference (d)a | PLCRC’s most recent phase 2017-Aug’19 (n = 3671) | Standardized difference (d)a |
|---|---|---|---|---|---|---|---|
| Age at diagnosis | 69.3 ± 10.8 | 64.9 ± 10.5 | 0.41 | 64.6 ± 10.2 | 0.45 | 65.0 ± 10.6 | 0.40 |
| < 55 years | 6476 (9%) | 733 (15%) | 170 (16%) | 563 (15%) | |||
| 55–64 years | 15,248 (21%) | 1470 (31%) | 350 (32%) | 1120 (31%) | |||
| 65–74 years | 26,602 (37%) | 1722 (36%) | 395 (36%) | 1327 (36%) | |||
| 75–84 years | 19,482 (27%) | 729 (15%) | 153 (14%) | 576 (16%) | |||
| ≥ 85 years | 4877 (7%) | 105 (2%) | 20 (2%) | 85 (2%) | |||
| Sex | 0.11 | 0.17 | 0.09 | ||||
| Male | 41,115 (57%) | 2949 (62%) | 704 (65%) | 2245 (61%) | |||
| Female | 31,570 (43%) | 1810 (38%) | 384 (35%) | 1426 (39%) | |||
| BMI at diagnosisb (kg/m2) | 26.6 ± 4.6 | 26.6 ± 4.8 | 0.01 | 25.9 ± 4.0 | 0.16 | 26.7 ± 4.9 | 0.03 |
| Underweight (< 18.5) | 228 (2%) | 10 (1%) | 1 (1%) | 9 (1%) | |||
| Normal weight (18.5–24.9) | 5252 (38%) | 502 (40%) | 78 (47%) | 424 (39%) | |||
| Overweight (25–29.9) | 5625 (41%) | 503 (40%) | 61 (37%) | 442 (41%) | |||
| Obese (≥ 30) | 2691 (20%) | 229 (18%) | 26 (16%) | 203 (19%) | |||
| Primary tumor locationc | 0.24 | 0.53 | 0.16 | ||||
| Rectum (C19.9, C20.9) | 22,426 (31%) | 2025 (43%) | 610 (56%) | 1415 (39%) | |||
| Colon (C18.0–18.7) | 50,259 (69%) | 2734 (57%) | 478 (44%) | 2256 (61%) | |||
| Right colon (C18.0–18.4) | 24,244 (48%) | 1330 (49%) | 200 (42%) | 1130 (50%) | |||
| Left colon (C18.5–18.7) | 24,634 (49%) | 1359 (50%) | 269 (56%) | 1090 (48%) | |||
| Colon unspecified (C18.8–18.9) | 1381 (3%) | 45 (2%) | 9 (2%) | 36 (2%) | |||
| TNM | 0.24 | 0.33 | 0.22 | ||||
| Stage I | 17,686 (24%) | 849 (18%) | 160 (15%) | 689 (19%) | |||
| Stage II | 17,951 (25%) | 1063 (22%) | 213 (20%) | 850 (23%) | |||
| Stage III | 21,707 (30%) | 1929 (41%) | 462 (42%) | 1467 (40%) | |||
| Stage IV | 15,341 (21%) | 918 (19%) | 253 (23%) | 665 (18%) | |||
| Location synchronous metastases | |||||||
| Liver | 11,218 (15%) | 722 (15%) | 0.01 | 202 (19%) | 0.08 | 520 (14%) | 0.04 |
| Lung | 3954 (5%) | 209 (4%) | 0.05 | 58 (5%) | 0.00 | 151 (4%) | 0.06 |
| Peritoneal | 3673 (5%) | 162 (3%) | 0.08 | 42 (4%) | 0.06 | 120 (3%) | 0.09 |
aStandardized differences (d) are differences in means or proportions divided by standard error; d > 0.20 indicate a large difference, d 0.10–0.20 indicate a small difference, and d < 0.10 indicate a negligible difference17,18.
bBMI at diagnosis for PLCRC only available when participants were enrolled at diagnosis and provided PROs (n = 1244); the NCR only collected height and weight in 2015, thus the reference values for BMI originate only from patients diagnosed in 2015 (n = 13,796).
cStandardized differences calculated over the proportion rectum versus colon tumors.